FinnGen study is funded by Business Finland and the pharmaceutical industry partners. The funding allocated for the first six years (2017-2023) was approximately 92 M €. FinnGen 3 agreement secured approximately 52 M € in new international investment.

The graph belows shows the FinnGen expenditure distribution for the first six years of the study (FinnGen 1 & 2). The data is based on December 2022 situation / budget forecast. 38% of the funding is used to cover costs related to biobank sample collection and handling. The next largest items of expenditure are data processing & analyses activities (19% of the budget, mainly personnel costs) and genotyping with ThermoFisher's array (12% of the budget). In addition, significant investments to IT and data security have been made (11% of the budget). Additional research data category (13%) includes costs related to new research activities launched during FinnGen2, such as collecting clinical data for selected disease areas, a questionnaire pilot, producing molecular profiling data to study the function of selected interesting genetic variants and a sub-study focusing on Alzheimer's disease.

Graph showing the expenditure distribution of FinnGen. The largest budget items are listed in the text. In addition, the graph contains the following items: Management, coordination and outreach (6%) and Meetings and travel (1%).

The total FunnGen budget exceeds 144 M €. Approximately 20 M € comes from Business Finland and the rest from thirteen international pharmaceutical industry partners: AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Scibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.